Results 1 to 10 of about 1,413 (68)

Dabigatran Etexilate Induces Cytotoxicity in Rat Gastric Epithelial Cell Line via Mitochondrial Reactive Oxygen Species Production

Cells, 2021
Dabigatran is a novel oral anticoagulant that directly inhibits free and fibrin-bound thrombins and exerts rapid and predictable anticoagulant effects. While the use of this reagent has been associated with an increased risk of gastrointestinal bleeding,
Hiromi Kurokawa, Atsushi Taninaka, Hidemi Shigekawa, Hirofumi Matsui   +3 more
doaj   +1 more source

Effects of Simvastatin on Pharmacokinetics and Anticoagulant Effects of Dabigatran in Healthy Subjects

Pharmaceuticals, 2023
Higher risk of major hemorrhage associated with concomitant use of dabigatran and simvastatin compared to other statins was previously reported with a suggestion of P-glycoprotein-mediated interaction. The aim of this study was to evaluate the effects of
Hyewon Chung, Jong-Min Kim, Jin-Woo Park, Jihyeon Noh, Kyoung-Ah Kim, Ji-Young Park   +5 more
doaj   +1 more source

Dabigatran: Clinical correlation of drug and its dose with risk of stroke and bleeding

Perspectives in Clinical Research, 2023
Background: Dabigatran is the first oral direct thrombin inhibitor which is endorsed by Food and Drug Administration in the prevention of embolic events in patients with nonvalvular atrial fibrillation.
Anitta Shaji, Doody Thomas, Midhuna Saju, Suja Abraham, Ramdas Nayak   +4 more
doaj   +1 more source

Pharmacokinetics and Pharmacogenetics of Dabigatran

Рациональная фармакотерапия в кардиологии, 2021
Dabigatran etexilate is a prodrug of dabigatran, a oral direct inhibitor of thrombin. Pharmacokinetics of dabigatran etexilate doesn’t have the disadvantages of vitamin K antagonists.
A. V. Savinova, V. S. Dobrodeeva, M. M. Petrova, R. F. Nasyrova, N. A. Shnayder   +4 more
doaj   +1 more source

Dabigatran in Cerebral Sinus Vein Thrombosis and Thrombophilia

Life, 2022
Background and Purpose: Thrombophilic gene alterations are a major risk factor for cerebral sinus vein thrombosis (CSVT). Up to 30% of all patients with cerebral sinus vein thrombosis (CSVT) are found to have thrombophilic defects such as prothrombin ...
Lukas Kellermair, Matthias W. G. Zeller, Caterina Kulyk, Josef Tomasits, Tim J. von Oertzen, Milan R. Vosko   +5 more
doaj   +1 more source

Impact of Dabigatran Treatment on Rotation Thromboelastometry

Clinical and Applied Thrombosis/Hemostasis, 2021
A rapid and reliable assessment of the dabigatran effect is desirable in dabigatran treated patients with uncontrolled bleeding or before acute surgery.
Juraj Sokol MD, PhD, Frantisek Nehaj MD, Jela Ivankova RNDr, Michal Mokan MD, PhD, Jana Zolkova RNDr, Lenka Lisa MD, PhD, Ludmila Linekova MD, Marian Mokan MD, DSc, FRCP Edin, Jan Stasko MD, PhD   +8 more
doaj   +1 more source

The preoperative management of dabigatran and its specific antidote idarucizumab in patients with nonvalvular atrial fibrillation: Case reports [PDF]

Arhiv za farmaciju, 2020
Dabigatran is a novel oral anticoagulant preferred due to its ease of use, favorable pharmacokinetics, decreased potential for drug-drug interactions, and the lack of monitoring requirements.
Tomić Milan
doaj   +1 more source

Measurement of Dabigatran Concentration Using Finger Prick Dried Blood Spot Sample Collection

Frontiers in Pharmacology, 2021
Background and Purpose: Real-world laboratory monitoring of dabigatran activity is challenging. The purpose of the present study was to demonstrate the feasibility and accuracy of finger prick sampling with dried blood spot (fpDBS) cards in measuring the
Shin-Yi Lin, Shin-Yi Lin, Yu-Fong Peng, Chih-Fen Huang, Chih-Fen Huang, Ching-Hua Kuo, Sung-Chun Tang, Jiann-Shing Jeng   +7 more
doaj   +1 more source

Relationship between plasma dabigatran concentration and activated partial thromboplastin time in Japanese patients with non-valvular atrial fibrillation

Journal of Arrhythmia, 2015
Background: Activated partial thromboplastin time (aPTT) is recommended for monitoring anticoagulant activity in dabigatran-treated patients; however, there are limited data in Japanese patients.
Daiki Shimomura, Yoshihisa Nakagawa, MD, Hirokazu Kondo, MD, Toshihiro Tamura, MD, Masashi Amano, MD, Yukiko Hayama, MD, Naoaki Onishi, MD, Yodo Tamaki, MD, Makoto Miyake, MD, Kazuaki Kaitani, MD, Chisato Izumi, MD, Masahiko Hayashida, Aya Fukuda, Fumihiko Nakamura, MD, Seiji Kawano, MD   +14 more
doaj   +1 more source

HOW TO USE DABIGATRAN IN PATIENTS WITH ATRIAL FIBRILLATION

Рациональная фармакотерапия в кардиологии, 2015
Dabigatran is the new oral anticoagulant that directly inhibits thrombin (factor IIa). In RE-LY clinical trial dabigatran 150 mg b.i.d was more effective than warfarin in prevention of ischemic stroke and systemic embolic events in more than 18000 ...
S. V. Moiseev
doaj   +3 more sources